MED19 and prostate carcinoma: For instance, CARM1 is found to be overexpressed in breast cancer and prostate carcinoma [54, 55], mediator complex subunit 19 (MED19) is upregulated in bladder cancer [56], and nuclear receptor co-activator 5 (NCOA5) expression is elevated in colorectal cancer [57].